Merck & Co.
AWARDS
NEWS
Bavencio is an anti-PD-L1 checkpoint inhibitor co-developed by Merck KGaA, Darmstadt, German and Pfizer via EMD Serono, a business unit of the two companies.
The anti-PD-1 therapy was approved by the U.S. Food and Drug Administration alone for first-line treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
It was a busy week for clinical trial updates. Here’s a look.
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.
Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration (FDA) has a busy two-week period coming up for drug approvals. Here’s a look.
JOBS
IN THE PRESS